# Actinium Therapy for Late-stage Aggressive Sarcomas

Source: https://onco.cc/trials/nct07156565/  
OnCo record `nct07156565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of [Ac-225]RTX-2358 run by Ratio Therapeutics, Inc., now recruiting.

## Summary

Actinium Therapy for Late-stage Aggressive Sarcomas is a phase 1 interventional study registered as NCT07156565 by Ratio Therapeutics, Inc., with 48 participants planned, started 2025-11-12. Conditions recorded: Advanced Soft Tissue Sarcoma. Interventions recorded: [Ac 225]RTX-2358 and [Cu64]LNTH-1363S.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07156565
- Phase: 1
- Setting: A Seamless Phase 1/2 Open-label Study to Evaluate the Safety, Determine the Maximum Tolerated Dose of Administered Activity, and Evaluate the Efficacy of the Therapeutic Radiopharmaceutical [Ac 225]-RTX-2358 in the Treatment of Relapsed or Refractory Sarcoma
- Sponsor: Ratio Therapeutics, Inc.
- Enrolled: 48

## Sources

- ClinicalTrials.gov NCT07156565: https://clinicaltrials.gov/study/NCT07156565

## Connected records

- cancers: [Soft tissue sarcoma of the extremity (localised and advanced)](https://onco.cc/cancers/extremity-soft-tissue-sarcoma/)
- drugs: [[Ac-225]RTX-2358](https://onco.cc/drugs/rtx-2358/)
- companies: [Ratio Therapeutics](https://onco.cc/companies/ratio-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07156565.json